.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Predict branded drug patent expiration
  • Set up watchlists for daily email updates

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Abarelix - Generic Drug Details

« Back to Dashboard

What are the generic drug sources, and freedom to operate, for abarelix?

Abarelix is the generic ingredient in one branded drug marketed by Speciality European and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Abarelix has fifty-nine patent family members in thirty-four countries.

Summary for Generic Name: abarelix

Tradenames:1
Patents:3
Applicants:1
NDAs:1
Bulk Api Vendors: see list16
Clinical Trials: see list1
Patent Applications: see list5,752
Drug Prices:see low prices
DailyMed Link:abarelix at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003DISCNNoNo6,699,833► SubscribeY ► Subscribe
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003DISCNNoNo5,968,895► SubscribeY ► Subscribe
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 2003DISCNNoNo6,180,608► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: abarelix

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 20035,843,901► Subscribe
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 20036,699,833► Subscribe
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 20035,968,895► Subscribe
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 20036,455,499► Subscribe
Speciality European
PLENAXIS
abarelix
INJECTABLE;INTRAMUSCULAR021320-001Nov 25, 20036,423,686► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: abarelix

Country Document Number Estimated Expiration
European Patent Office2316471► Subscribe
New Zealand568189► Subscribe
Denmark1398037► Subscribe
Russian Federation2202371► Subscribe
Turkey9901382► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ABARELIX

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90014-9Sweden► SubscribePRODUCT NAME: ABARELIX
C0015France► SubscribePRODUCT NAME: ABARELIX, EVENTUELLEMENT SOUS FORME DE SEL PHARMACEUTIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE IN FRANCE: 69026150 DU 20101126; REGISTRATION NO/DATE AT EEC: 57890.00.00 DU 20050922
2011 00004Denmark► SubscribePRODUCT NAME: ABARELIX, EVENTUELT I FORM AF ET FARMACEUTISK SALT; NAT. REG. NO/DATE: 44637 (DK) 20100827; FIRST REG. NO/DATE: DE 578900000 20050922
C/GB11/006United Kingdom► SubscribePRODUCT NAME: ABARELIX, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: DE - 20050922; UK PL32828/001 20100917
00484Netherlands► SubscribePRODUCT NAME: ABARELIX, EVENTUEEL IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NAT. REGISTRATION NO/DATE: RVG 104389 20101220; FIRST REGISTRATION: 57890.00.00 20050922
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc